WOBURN, Mass., Nov. 14, 2025 /PRNewswire/ -- Micro Medical Solutions (MMS), an innovative medical device company focused on improving outcomes for patients suffering from Critical Limb Threatening Ischemia (CLTI), today announced the appointment of Vince Burgess and John Dahldorf to its Board of Directors. They join George Quinoy, Chairman of the Board and President & Chief Executive Officer, and Dr. Ron Solar, Board Member, as MMS strengthens its leadership team in preparation for commercializa

CAESAREA, Israel, Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which

NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Leb

TORRANCE, Calif., Nov. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2025. Highlights "We experienced a 38% decline in net revenues for the three months ended September 30, 2025 as compared to the same period in 2024 due to ongoing competition from gen

For Immediate Release: November 14, 2025 The U.S. Food and Drug Administration today announced it is taking action to approve new labeling submitted by the company that includes the addition of a Boxed Warning, the agency’s most prominent safety warning, to Elevidys (delandistrogene moxeparvovec-rokl), and that the indication section of the labeling limits the therapy’s indication to ambulatory patients four years of age and older with Duchenne muscular dystrophy (DMD). These actions follow repo

FDA Safety Communication – November 14, 2025 Summary of the Issue In June 2025, FDA issued a safety communication, “ FDA Investigating Deaths Due to Acute Liver Failure in Non-ambulatory Duchenne Muscular Dystrophy Patients Following ELEVIDYS ,” to provide information on two reports of fatal acute liver failure following treatment with Elevidys (delandistrogene moxeparvovec-rokl) of non-ambulatory pediatric male patients with Duchenne Muscular Dystrophy (DMD). FDA also listed hepatotoxicity-asso

Texas Cannabis Clinic Reassures Patients: Medical Cannabis Program Remains Safe, Legal, and Fully Operational Patients in the Texas medical cannabis program can rest easy, the recent federal changes simply don’t apply to our patients or our program’s products.” — Dr Matthew Brimberry AUSTIN, TX, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Following the federal government’s reopening last night, headlines have focused on sweeping new restrictions for hemp-derived products tucked into

Dr. Greenberg brings NeuroSpine Center of Wisconsin’s advanced non-surgical spine, joint, & regenerative medicine treatments to Madison via Stoughton Hospital. I’m truly excited to return to the Madison area - where I began my medical career... regenerative treatment options that reflect the latest innovations in spine and musculoskeletal medicine.” — Dr. Jared S. Greenberg, MD, at NeuroSpine Center of Wisconsin. STOUGHTON, WI, UNITED STATES, November 14, 2025 / EINPresswire.com / -- NeuroSpine

BOSTON, Nov. 14, 2025 /PRNewswire/ -- Volta Labs, a leader in automation for genomics, and New England Biolabs® (NEB®), a world-renowned provider of life science reagents, today announced a co-development partnership to expand the portfolio of NEBNext® reagents available on the Callisto™ Sample Preparation Platform. The collaboration combines Volta's fully automated NGS sample preparation system with NEB's trusted, high-performance NEBNext NGS sample preparation kits to deliver reproducible, w

Bengaluru: Denmark's Zealand Pharma said on Thursday it has paused the development of an early-stage obesity drug candidate as it shifts focus to more promising programs. The drug dapiglutide , a GLP-1/GLP-2 receptor dual agonist designed for weight loss and reducing low-grade inflammation associated with obesity, was previously planned to enter mid-stage trials this year. "Zealand is pausing development in recognition of the increasingly crowded GLP-1 space, with demonstration of dapiglutide 's